Hemoteq's Fancy New Coat

Hemoteq's hemocompatible coating for medical devices could help address one of the last remaining concerns about drug-eluting stents: the risk of subacute and late thrombosis. But for a small company to compete in drug-eluting stents isn't easy.

By David Cassak

When officials of Angiotech Pharmaceuticals Inc. went into the EU Patent Court in Munich this past January, seeking the...

More from Innovation

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.